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Pulmonary complications are prevalent in the critically ill neurological population. Respiratory failure, pneumonia, acute
lung injury and the acute respiratory distress syndrome (ALI/ARDS), pulmonary edema, pulmonary contusions and
pneumo/hemothorax, and pulmonary embolism are frequently encountered in the setting of severe brain injury. Direct brain
injury, depressed level of consciousness and inability to protect the airway, disruption of natural defense barriers, decreased
mobility, and secondary neurological insults inherent to severe brain injury are the main cause of pulmonary complications in
critically ill neurological patients. Prevention strategies and current and future therapies need to be implemented to avoid and
treat the development of these life-threatening medical complications.
1. Introduction
Pulmonary complications are very prevalent in the critically-
ill neurological population. Respiratory failure, pneumonia,
pleural eﬀusions and empyema, acute lung injury and
the acute respiratory distress syndrome (ALI/ARDS), pul-
monary edema, and pulmonary embolism (PE) from venous
thromboembolism (VTE) are frequently encountered in this
patient population [1–7]. In addition, direct chest trauma
and patients with traumatic brain injury (TBI) are not
exempt from direct complications such as rib fractures, flail
chest, lung contusions, and hemo/pneumothorax. Unfortu-
nately, the development of these complications extends the
patient’s need for care in the intensive care unit (ICU) and
prevents early mobilization, and this increases the likelihood
of developing secondary disability.
Direct brain injury, depressed level of consciousness and
inability to protect the airway, disruption of natural defense
barriers, decreasedmobility, and secondary physiopathologic
insults inherent to severe brain injury are the main cause
of pulmonary complications in critically-ill neurological
patients. The goal in the ICU is to prevent, treat, and
optimize hypoxemia and maintain oxygen delivery to limit
secondary neurological insults. In the absence of feasible
pharmacological agents to target these goals, prevention
strategies to minimize pulmonary complications such as use
of bedside techniques such as thoracentesis, closed thora-
costomies (chest tubes), lung-protective ventilator strategies,
bundles for prevention of ventilator associated pneumonias
(VAP), and deep venous thrombosis (DVT) prophylaxis
are the cornerstone in the prevention and management of
pulmonary complications in severe brain injured patients.
Finally, additional strategies to target physiopathological
end-points such as inflammation may need to be developed,
studied in clinical trials, and deployed to clinical practice, to
optimize the outcomes in this patient population. This paper
summarizes the most important pulmonary complications
encountered in the critically-ill neurological population.
2. Pulmonary Complications Related to
Direct Chest Trauma
Patients who sustain TBI are often at risk for the devel-
opment of other traumatic injuries such as rib fractures,
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lung contusions, flail chest, and pneumo/hemothorax. The
implementation of a routine standardized assessment of
the traumatized victim provides a highly sensitive protocol
to diagnose these injuries [8]. A traumatic pneumothorax,
defined as the entry of air into the pleural space, occurs
after both penetrating and nonpenetrating thoracic injuries.
A simple pneumothorax occurs when there is no com-
munication with the external environment or any shift of
mediastinal structures (Figure 1), an open pneumothorax
occurs when a communication or fistula exists between
the pleural space and the environment (sucking wound),
and finally, a tension pneumothorax occurs when escape of
pleural air to the environment is prevented, and increasing
intrapleural pressure leads to shift in mediastinal structures
with associated hemodynamic compromise. Treatment of a
small pneumothorax in a traumatized victim undergoing
positive pressure ventilation requires the use of chest tubes,
and a conservative approach with normobaric hyperoxia
is not an alternative. However, patients with blunt trauma
breathing spontaneously and with occult pneumothoraces
could be safely observed [9]. Open pneumothoraces require
(a) chest tube, (b) mechanical ventilation, and (c) imme-
diate surgical repair of the wound. Treatment of tension
pneumothorax requires the use of immediate decompres-
sion (needle thoracostomy) and/or rapid placement of a
chest tube. The persistence of air leak and pneumothorax
is indicative of a bronchopleural fistula and therefore
requires immediate surgical revision with thoracotomy
(Figure 1).
A hemothorax is the accumulation of blood in the pleural
space and may be the cause of respiratory distress, pain,
hypoxia, and circulatory arrest. A massive hemothorax is
defined as the presence of more than 1000 cc of blood or the
chest tube output of more than 200 cc/h [8]. The treatment
of a hemothorax requires: (a) restitution of circulatory blood
volume if needed, (b) oxygen supply and restoring the
airway, and (c) closed thoracostomies (chest tubes).
A flail chest results when three or more adjacent ribs are
fractured at two diﬀerent points, allowing a freely moving
segment of the chest wall. This pattern of fractures is
often associated with severe pain, underlying pulmonary
contusions, and respiratory failure secondary to paradoxical
movements of the chest wall. Most of the times patients
require mechanical ventilation and pain control but the
decision to intubate may require individualization.
3. Respiratory Failure and Pneumonia
Neurologic related respiratory failure from severe central
nervous system dysfunction is one of the most frequent
reasons for initiating mechanical ventilation [10]. Among
the causes of neurologic dysfunction, structural causes
such as ischemic stroke (AIS), hemorrhages (intracerebral
hemorrhage (ICH) and subarachnoid hemorrhage (SAH)),
and traumatic brain injury (TBI) carry the worst prognosis
and are the greatest challenge to critical care specialists
based on the interaction between hypoxemia and secondary
neurological insults.
Figure 1: Chest X-ray of an ARDS victim who has developed
multiple pneumothoraces secondary to a bronchopleural fistula.
In a recently published retrospective multicenter cohort
study from a prospective compiled and maintained registry,
Pelosi et al. studied the epidemiology, clinical characteristics,
and clinical practices in relation to mechanical ventilation in
a cohort of critically-ill neurological patients. Though SAH
patients were excluded, this study is an excellent description
of day-to-day practices across diﬀerent types of ICUs around
the globe. Not surprisingly, neurological patients had lower
Glasgow Coma Scale (GCS) on admission, more ICU and
ventilator-days, had more early tracheostomies, more VAP
rates, but more interestingly, the rate of reintubation was
similar to those of nonneurological patients. In this sense,
this study provides support that mental status and GCS may
not matter at the time of extubation [11], as GCS was higher
in nonneurological patients and the rate of reintubation
was the same. Though the Pelosi study is important [1], it
does not answer the question of which neurological patients
are more likely to get “stuck” on the ventilator or need
early reintubation. The interaction with disease severity, age,
neurological diagnosis, and important variables that worry
all critical care specialists at the time of extubation such as
characteristics and management of secretions, development
of atelectasis due to hypoventilation [12], cranial nerve
involvement (pupillary abnormalities, absence of gag, etc.)
are missing in this analysis. These questions may need to
be answered in diﬀerent prospective clinical trials, but in
the meantime, clinical expertise may need to guide the best
approach to a particular patient.
Pneumonia is a common complication of severe brain
injury and can occur in up to 60% of patients [13] as these
patients are prone to aspirate stomach contents. Similarly,
VAP is a preventable secondary consequence of prolonged
intubation and mechanical ventilation. VAP is pneumonia
that develops in an intubated patient after 48 hours or
more of ventilatory support [14]. Critically-ill neurological
patients that are mechanically ventilated are at an increased
risk of VAP due to factors such as decreased level of con-
sciousness; dry, open mouth; microaspiration of secretions
[15]. Patients with severe brain injury tend to be on mechan-
ical ventilation longer than medically intubated patients, and
VAP in the neurologic ICU can further increase the length
of stay (LOS) [16]. In patients with severe ischemic stroke,
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the development of VAP is associated with a 3-fold increase
of in-hospital mortality [17]. The implementation of VAP
bundles including oral care has been shown to decrease
the rate of VAP in critically-ill neurological patients [18].
Additional measures to decrease VAP include daily vacation
sedation to examine readiness for extubation, management
of upper airway secretions with closed aspiration systems,
and strict control of endotracheal-tube cuﬀ pressures,
policies related to hand hygiene, head elevation at 45◦,
oral hygiene with chlorhexidine preparations, along with
stress ulcer prophylaxis with H2 or proton-pump inhibitors
[19].
Though neurological patients experience more early
tracheotomies in general [1], this practice has not been
associated with improved patient outcomes, particularly
mortality or onset of VAP [20, 21]. Accumulation of fluid
in the pleural space and bacterial infection may result in
empyema. Treatment of empyema and complicated pleural
eﬀusions requires evacuation of the infected material via
chest tube and antibiotic regimen.
4. ALI and ARDS
ALI and the more severe form of lung injury, the ARDS,
are a continuum of inflammatory responses following direct
or indirect insults to the lung and clinically recognized by
the onset of hypoxemia, reduced pulmonary compliance,
and radiographic appearance of bilateral infiltrates [22]. The
incidence of ALI/ARDS syndrome has been reported in 20–
25% of patients with isolated traumatic brain injury (TBI)
[23, 24]. In patients with SAH an incidence of 20–30%
has been reported as well [2, 3], and in acute ischemic
stroke (AIS), a recent epidemiological study reported that
the cumulative incidence of ARDS from 1994 to 2008 was
4% [6]. In all reports, the mortality and outcomes are
substantially the worst [3, 6, 24] (Figure 2).
ARDS is defined as a syndrome characterized by acute
onset of bilateral lung infiltrates consistent with pulmonary
edema (Figure 3), absence of signs of left atrial hyper-
tension (usually a pulmonary artery occlusion pressure
(PAOP) of < 18mmHg), and hypoxemia with a PaO2/FiO2
ratio of < 200. Patients with these criteria but with
PaO2/FiO2 ratios < 300 are classified as ALI [22]. Risk
factors for the development of ALI/ARDS in brain injured
patients are the severity of the initial brain injury (lower
GCS scores), in-hospital induced hypertension [25], and
extracranial factors such as younger age, male gender,
white race ethnicity, history of HTN, DM, and COPD,
and the development of sepsis has been implicated as well
[6, 24].
The physiopathology of ARDS/ALI is rather complex.
Initial studies suggested that the development of NPE in
patients with TBI [26] and hemorrhagic stroke wash more
frequent in those patients who had higher intracranial
pressures (ICP) and low cerebral perfusion pressures (CPP,
mean arterial pressure (MAP-ICP) [27]. The importance
of these landmark studies is that the development of NPE
occurred in the absence of clear lung injury and normal chest
Figure 2: Chest X-ray of an ARDS victim that suﬀered a grade 4
SAH.
Figure 3: Pulmonary edema from volume overload as complication
of Triple H Therapy in a patient with Grade 4 SAH. Note distended
pulmonary arteries and prominent cardiac silhouette.
X-ray (CXR) on admission, suggesting that brain injury was
a risk factor for this phenomenon. Explanations for these
observations were based on what is known as the “blast
injury,” which explains that a surge in adrenergic response is
translated into increased capillary pressures in the lung bed,
endothelial damage, and subsequent capillary leak into the
alveoli and pulmonary interstitium [28]. In addition, inflam-
matory responses related to the production of mediators
such as IL-6 may explain the development of NPE [29, 30].
To this end, a “double hit” model has been proposed where
patients suﬀering severe brain injury experience a “first
hit” with an adrenergic surge and systemic production of
inflammatory mediators, making the lung more susceptible
to injury, and a “second hit” from extracorporeal variables
such as infections, transfusions, and mechanical ventilation
[31].
The role of mechanical ventilation in the physiopathol-
ogy of ALI/ARDS has been studied extensively. The onset of
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systemic inflammation in the setting of brain injury coupled
with conventional modalities of mechanical ventilation used
in the management of brain injury such as hyperventi-
lation for permissive hypocapnia may be associated with
more lung injury [32]. The use of ventilator modalities to
achieve mild permissive hypocapnia (PaCO2 30–35mmHg)
may be associated with the use of tidal volumes (Tv)
larger than 6–8ml/kg, which have been associated with the
ventilator-induced ling injury (VILI), a syndrome indistin-
guishable from ARDS [33] and related to overdistention
during mechanical ventilation (volutrauma), recruitment-
derecruitment of collapsed alveoli (atelectrauma), and acti-
vation of inflammatory processes (biotrauma) [31].
Conventional ventilatory support in severe brain injured
patients relies on the use of assist-control ventilation [1].
Most practitioners would aim at ventilating with low tidal
volumes (6–8ml/kg of PBW), plateau pressures < 30 cm
H2O, and PEEP levels of 5–10 cmH2O, which may be
considered controversial [34]. In certain cases and refrac-
tory hypoxemia rescue ventilation with higher positive
end expiratory pressure (PEEP), prone positioning and
recruitment, airway pressure release ventilation (APRV),
high frequency oscillation (HFOV), tracheal gas insuﬄation
(TGI), extracorporeal membrane oxygenation (ECMO), and
CO2 removal (AV-ECCO2R) may need to be instituted [31,
34]. Recent observational studies have demonstrated that
practitioners may use lower PEEP levels in neurological
patients [35], perhaps of fear of aﬀecting intracranial
pressures (ICPS). Application of PEEP in brain injury may be
associated with three responses: increase or decrease on ICP
or no change at all, depending on the end result at the lung
and gas exchange level. If PEEP induces alveolar recruitment,
a reduction in PaCO2 would be seen, with a decrease in ICP.
If PEEP induces alveolar hyperinflation only and no net eﬀect
on ventilation, there could be an increase in the PaCO2, with
a concurrent increase in ICP [36]. Lastly, the application
of PEEP in those patients in whom alveolar recruitment
occurs, but the predominant eﬀect is an improvement in
oxygenation rather than a prominent decrease in PaCO2 due
to a reduction in dead space, a no significant change in ICP
would be expected [36]. At this time, it seems that the use of
PEEP to treat ALI/ARDS may be appropriate in the patient
with severe brain injury, provided that MAP is maintained
and close attention given to ICP and CPP as changes are
made. Several authors advocate for determination of cerebral
autoregulation to determine if patients may tolerate abrupt
changes in PEEP that could result in increased ICP, in those
with lost cerebral autoregulation [37]. Finally, the use of
steroids in the proliferative phase of ARDS is of questionable
use [35, 38–40].
Experimental animal models of induced hypothermia
in conjunction with lower ventilatory frequencies have
demonstrated the improvement of many variables of acute
lung injury such as neutrophil counts and inflammatory
markers, suggesting that the role of hypothermia in the
management of ALI/ARDS may be studied in clinical trials,
and newer applications in the management of ALI/ARDS
may be forthcoming [41].
5. Pulmonary Edema in the SAH Population
Symptomatic cerebral vasospasm and delayed cerebral
ischemia continue to be a major etiology for significant
morbidity for patients suﬀering from acute, aneurysmal
subarachnoid hemorrhage (SAH) [42] (Figure 3). Triple
H therapy, which consists of hypertension, hemodilution,
and hypervolemic therapy, has been a mainstay of the
medical therapy for treating symptomatic vasospasm for the
past few decades [43]. Each component of this therapy is
geared towards augmenting cerebral blood flow (CBF) and
perfusion pressure of the brain. Despite a paucity of evidence
for indications, triple H therapy has been widely used around
the world as both prophylaxis and treatment for cerebral
vasospasm. The timing of triggering the initial therapy as
well as how each component is used depends primarily on
the need of each patient since SAH can be a heterogeneous
(i.e., low versus high grade SAH has a dramatically diﬀerent
natural course of illness) and dynamic disease. However,
even for the same patient scenario, there is a wide variety
of practice patterns in using this therapy, mainly due to
lack of evidence for guiding clinicians. According to a
recently published survey, most neurointensivists initiated
triple H therapy in order to treat symptomatic vasospasm
[44]. Therefore, most of the controversies existed in the
setting of prophylactic use. While the data for or against
such prophylactic use is limited, literature indicates that
there is no diﬀerence in outcomes between placebo and
triple H therapy when used as a prophylaxis against cerebral
vasospasm [45, 46]. Regardless of whether it is used as a
prophylaxis or treatment for active vasospasm, hypervolemia
and hemodilution frequently lead to medical complications
most often as pulmonary edema and anemia, which could
be associated with worst outcomes in SAH patients [47].
Intravascular volume expansion and targeting a certain level
of hemoglobin may provide augmentation of cardiac output
and therefore ultimately improve the delivery of oxygen.
However, the optimal target for hemoglobin is still unknown
but microdialysis studies have shown than in the setting of
vasospasm hemoglobin levels lower than 9mg/dL may be
associated with metabolic crisis in the injured brain [48].
The potentially positive eﬀect of hemodilution, especially
while ischemic injury is ongoing, may be provided by triple
H therapy, but there is also a ceiling eﬀect. No matter
how much preload is expanded, the cardiac output does
not infinitely increase and thus reaches a certain level
of plateau. Oxygen carrying capacity also has the same
limitation. Furthermore, in order for the injured and actively
ischemic brain to receive adequate oxygen, gas exchange in
the lungs must occur optimally. This rather simple, and
yet important physiologic concept is often overlooked as
emphasis on saving the brain and allowing lung injury
such as pulmonary edema is often done. Treating physicians
need to understand that there will be a fine balance
between optimizing the CBF with hemodilution and the
extent of concurrent pulmonary complications, which may
adversely aﬀect the ultimate goal of delivery of oxygen and
flow to the injured brain. This concept has led to more
emphasis on hypertension [49] while ensuring an euvolemic
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state rather than creating an overly hypervolemic state by
arbitrarily using endpoints or surrogates of intravascular
volume status [50]. Even today, many centers have central
venous pressure (CVP) targets of greater 10mmHg and
pulmonary capillary wedge pressure greater than 12mmHg
as hemodynamic end points. It turns out neither of these
variables is accurate surrogate for assessing intravascular
volume status and has led to unacceptably high incidence
of pulmonary edema which again compromises the ultimate
delivery of oxygen to the ischemic brain (Figure 3). A recent
systematic review of analyzing CVP has demonstrated a
poor relationship between CVP and intravascular volume
status and reports that increasing the value of CVP to an
arbitrarily determined value does not lead to a positive
hemodynamic response [51]. The debate regarding the use of
triple H therapy and fine balance between maximizing CBF
in the setting of pulmonary edema may continue, and the
answer may be similar to many other controversial topics:
individualized, case-by-case decisions. In any event, the
principle of adequate gas exchange needs to be conveyed and
achieved in order to successfully optimize brain oxygenation.
Current guidelines for the management of SAH support
the maintenance of euvolemia rather than hypervolemia
[52].
6. Neurogenic Pulmonary Edema
Neurogenic pulmonary edema (NPE) has been reported
with a number of proposed mechanisms. While the exact
locations and circuits involved in the central nervous system
(CNS) have not been clearly identified, this uncommon
but potentially life-threatening condition may occur in the
setting of acute, severe brain injuries including traumatic
brain injury, intracerebral hemorrhage (ICH), and even in
seizures. Sudden rise in intracranial pressure (ICP) such as in
SAH or ICH, hypothalamic involvement, rapidly occurring
sympathetic surge, increased systemic vascular resistance
(SVR) have all been implicated in pathophysiology [53].
Elevated tone of venous circulation results in more venous
return. Increase in hydrostatic pressure in the pulmonary
vasculature may lead to interstitial edema formation [31].
Complicating the picture further, elevation in SVR
raises afterload for the heart, which in turn can lead to a
similar pathophysiology as cardiogenic pulmonary edema
with worsening left ventricular failure and further edema
formation in the pulmonary interstitial spaces. This entity
is a diagnosis of exclusion and requires ruling out primary
causes such as exacerbation of congestive heart failure, aspi-
ration pneumonia, pulmonary contusion, and other disease
processes that may cause pulmonary edema formation. NPE
has a characteristic, rapid formation of edema typically
occurring in a few hours after the onset of CNS injury.
Intracranial hypertension is common and the treatment
should focus on promptly treating ICP and optimizing
cerebral perfusion pressure while addressing the underlying
brain injury. Since this is a multisystem failure involving
brain, heart, lungs as well as the peripheral vasculature,
care should be given to ensure euvolemic state, support the
Figure 4: Saddle pulmonary embolism (white arrow) in a patient
with SAH.
contractility and vascular tone, and resuscitate the brain all
simultaneously.
7. Pulmonary Embolism
Venous thromboembolism (VTE) is a frequent and seri-
ous disease that encompasses both DVT and PE [54]
(Figure 4). The epidemiology of deep venous thrombosis
and pulmonary embolism in severe brain injured patients
varies according to the population studied, injury severity,
associated comorbidities and injuries, and the diagnostic
methods. In trauma patients, the prevalence of DVT is 18–
60% [55–57] and that of PE is 4–22% [58]. Studies in cohorts
of ICH patients demonstrate a prevalence of 2% for PE and
1% for DVT [5]. In the SAH population, the prevalence of PE
is < 1% and of DVT is 5–7% [2]. The eﬀects of VTE may be
detrimental for the critically-ill neurological patient, leading
to postphlebitic syndrome, recurrent VTE, and potentially
PE with a mortality rate of 9–50%. Clinical diagnosis of
VTE is very diﬃcult, and the sensitivity and specificity of
clinical exam are very poor. Therefore, studying patients at
higher risk or with higher prevalence of risk factors for the
development of VTE requires use of invasive and noninvasive
testing.
Even with the use of pneumatic compression devices,
the higher incidence of DVT makes prophylactic heparin
therapy desirable. Mechanical devices for DVT prophylaxis
are considered to be a standard of care [59]. As opposed to
pharmacological prophylaxis, mechanical devices may min-
imize hemorrhagic complications but may not suﬃciently
reduce the VTE rates. The adverse rates of hemorrhagic
complications with pharmacological prophylaxis compared
with the rates of VTE postprocedure are not well studied, and
the optimal method of prophylaxis in neurosurgical patients
(mechanical, pharmacological, or both) remains controver-
sial. A recent study in neurosurgical patients showed that
the majority of DVTs occurred within the first week after
neurosurgical procedures and that the use of early subcu-
taneous heparin (at either 24 or 48 hours) was associated
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with a 43% reduction of developing a lower-extremity DVT,
without an increase in surgical site hemorrhage without
association of pharmacological prophylaxis with overall PE
occurrence [59]. In general, severe brain injured patients
benefit from early use of pharmacological prophylaxis for
VTE. After craniotomy, low dose subcutaneous heparin
(5000U BID or TID) starting after the second day signifi-
cantly reduces the frequency of venous thromboembolism,
with no increase in intracranial bleeding [60]. Treatment
with low molecular weight heparin (i.e., enoxaparin 40mg
daily) is a reasonable alternative if renal function is nor-
mal, and the results of recent studies suggest that both
are equally eﬀective with similar rates of heparin-induced
thrombocytopenia [61]. When contraindicated, the use of
inferior vena cava filters may be necessary in the short term
[59].
8. Conclusions
Pulmonary complications are very prevalent in critically-
ill neurological patients. Critical care specialists and pro-
fessionals providing care for these patients must have a
thorough understanding of their physiopathology, diagnostic
methodologies, treatment alternatives, and overall impact on
patient’s outcomes.
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